Optimizing the Treatment of Acute Kidney Injury Caused by High-Dose Methotrexate: Integrating New Guidelines to Improve Patient Care

This activity, certified for CME/CE/CPE credit, is jointly provided by

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advance degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners' knowledge, competence and performance in both community and academic practice settings.

Release date: June 3, 2020

Expiration date: May 10, 2021

Accredited Provider

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net

Estimated time to complete activity: 1.0 hour

In Collaboration With

The ASCO Post
94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: editor@ascopost.com

This activity is supported by an unrestricted educational grant from BTG International, Inc.

Intended Audience

The activity's target audience will consist of medical and hematologic oncologists, nephrologists, nurse practitioners, physician assistants, oncology pharmacists, clinical nurse specialists, and other clinicians who care for people with cancer.

Learning Objectives

After completing this educational activity, participants should be able to:

  1. Identify patients treated with high-dose methotrexate (HDMTX) who are at risk for developing AKI
  2. Interpret the clinical implications of new guidelines into the treatment of acute kidney injury (AKI) in patients treated with HDMTX
  3. Plan strategies to integrate the new guidelines into practice

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the posttest and evaluation form) will receive a statement of credit.


Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nurses. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.


Pharmacists. This is a knowledge-based activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-20-048-H01-P. This program is designated for up to 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.



Zeyad Kanaan, MD: Advisory Board, BTG

Jaya Kala, MD: Speakers Bureau, BTG

Heidi Trinkman, PharmD: External Reviewer, Lexicomp; Speakers Bureau, Jazz Pharmaceuticals and BTG

Annenberg Center for Health Sciences at Eisenhower

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Content Reviewers

Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Institute (Reviewer) has served as a consultant for Pfizer and Eisai.

Lee Schwartzberg, MD, FACP, West Cancer Center has received honoraria from Amgen, Bristol-Myers Squibb, Pfizer and Tesaro; has served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Helsinn Therapeutics and Pfizer; is on the Speakers' Bureau for Genentech/Roche; and has receive research funding from Helsinn Therapeutics.

Nurse Planner

Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has no potential conflicts of interest to disclose.


Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.


This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population. The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

Learners must complete the learning assessment and evaluation.

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.

Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 CA-BRN
  • 1.00 ANCC
Course opens: 
Course expires: 

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 CA-BRN
  • 1.00 ANCC


Please login or register to take this course.